Permeation of losartan across human respiratory epithelium: An in vitro study with Calu-3 cells

F. He and G. MacGregor, Salt, blood pressure and cardiovascular disease, Curr. Opin. Cardiol. 22 (2007) 298-305; DOI: 10.1097/HCO.0b013e32814f1d8c.10.1097/HCO.0b013e32814f1d8cSearch in Google Scholar

R. Hernandez-Hernandez, B. Sosa-Canache, M. Velasco, M. J. Armas-Hernandez, M. C. Armas-Padilla and R. Cammarata, Angiotensin II receptor antagonists role in arterial hypertension, J. Hum. Hypertens. 16 (2002) S93-99; DOI: 10.1038/sj/jhh/1001352.Search in Google Scholar

M. W. Lo, M. R. Goldberg, J. B. McCrea, H. Lu, C. I. Furtek and T. D. Bjornsson, Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans, Clin. Pharmacol. Ther. 58 (1995) 641-649; DOI: 10.1016/0009-9236(95)90020-9.10.1016/0009-9236(95)90020-9Search in Google Scholar

H. R. Costantino, L. Illum, G. Brandt, P. H. Johnson and S. C. Quay, Intranasal delivery: physicochemical and therapeutic aspects, Int. J. Pharm. 337 (2007) 1-24; DOI: 10.1016/j.ijpharm.2007.03.025.10.1016/j.ijpharm.2007.03.02517475423Search in Google Scholar

M. I. Ugwoke, R. U. Agu, N. Verbeke and R. Kinget, Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives, Adv. Drug Deliv. Rev. 57 (2005) 1640-1665, DOI: 10.1016/j.addr.2005.07.009.10.1016/j.addr.2005.07.00916182408Search in Google Scholar

R. Agu and M. Ugwoke, In Situ and Ex Vivo Nasal Models for Preclinical Drug Development Studies, in Drug Absorption Studies in Situ, in Vivo and In Silico Models (Eds. C. Ehrhardt and K. Kim), AAPS Pharmaceutical Press, New York 2008, pp. 112-134; DOI: 10.1007/978-0-387-74901-3_5.10.1007/978-0-387-74901-3_5Search in Google Scholar

T. Yang, A. Hussain, J. Paulson, T. J. Abbruscato and F. Ahsan, Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies, Pharm. Res. 21 (2004) 1127-1136; DOI: 10.1023/B:PHAM.0000032998.84488.7a.10.1023/B:PHAM.0000032998.84488.7aSearch in Google Scholar

T. Seki, H. Kanbayashi, S. Chono, Y. Tabata and K. Morimoto, Effects of a sperminated gelatin on the nasal absorption of insulin, Int. J. Pharm. 338 (2007) 213-218; DOI: 10.1016/j.ijpharm.2007.02.004.10.1016/j.ijpharm.2007.02.00417346909Search in Google Scholar

R. U. Agu, S. Valiveti, D. C. Earles, M. Klausner, P. J. Hayden, D. P. Wermeling and A. L. Stinchcomb, Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats, Endocr. Res. 30 (2004) 455-467; DOI: 10.1081/ERC-200035957.10.1081/ERC-200035957Search in Google Scholar

N. V. Chemuturi, P. Hayden, M. Klausner and M. D. Donovan, Comparison of human tracheal/bronchial epithelial cell culture and bovine nasal respiratory explants for nasal drug transport studies, J. Pharm. Sci. 94 (2005) 1976-1985; DOI: 10.1002/jps.20404.10.1002/jps.2040416052562Search in Google Scholar

R. U. Agu, H. Vu Dang, M. Jorissen, R. Kinget and N. Verbeke, Metabolism and absorption enhancement of methionine enkephalin in human nasal epithelium, Peptides 25 (2004) 563-569; DOI: 10.1016/j.peptides.2004.02.019.10.1016/j.peptides.2004.02.01915165710Search in Google Scholar

N. Denora, V. Laquintana, A. Lopedota, M. Serra, L. Dazzi, G. Biggio, D. Pal, A. K. Mitra, A. Latrofa, G. Trapani and G. Liso, Novel L-dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety, Pharm. Res. 24 (2007) 1309-1324; DOI: 10.1007/s11095-007-9255-y.10.1007/s11095-007-9255-ySearch in Google Scholar

P. K. Yeung, A. Jamieson, G. J. Smith, D. Fice and P. T. Pollak, Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection, Int. J. Pharm. 204 (2000) 17-22; DOI: 10.1016/S0378-5173(00)00453-1.10.1016/S0378-5173(00)00453-1Search in Google Scholar

A. Soldner, L. Z. Benet, E. Mutschler and U. Christians, Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers, Br. J. Pharmacol. 129 (2000) 1235-1243; DOI: 10.1038/sj.bjp.0703150.10.1038/sj.bjp.0703150Search in Google Scholar

M. D. Ribadeneira, B. J. Aungst, C. J. Eyermann and S. M. Huang, Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption, Pharm. Res. 13 (1996) 227-233; DOI: 10.1023/A:1016086930019.10.1023/A:1016086930019Search in Google Scholar

O. von Richter, O. Burk, M. F. Fromm, K. P. Thon, M. Eichelbaum and K. T. Kivistö, Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens, Clin. Pharmacol. Ther. 75 (2004) 172-83; DOI: 10.1016/j.clpt.2003.10.008.10.1016/j.clpt.2003.10.008Search in Google Scholar

B. I. Florea, I. C. van der Sandt, S. M. Schrier, K. Kooiman, K. Deryckere, A. G. de Boer, H. E. Junginger and G. Borchard, Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3), Br. J. Pharmacol. 134 (2001) 1555-1563; DOI: 10.1038/sj.bjp.0704390.10.1038/sj.bjp.0704390Search in Google Scholar

T. Korjamo, P. Honkakoski, M. R. Toppinen, S. Niva, M. Reinisalo, J. J. Palmgrén and J. Mönkkönen, Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines, Eur. J. Pharm. Sci. 26 (2005) 266-279; DOI: 10.1016/j.ejps.2005.06.004.10.1016/j.ejps.2005.06.004Search in Google Scholar

Z. Shao, R. Krishnamoorthy and A. K. Mitra, Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations, Pharm. Res. 9 (1992) 1157-1163; DOI: 10.1023/A:1015847604654.10.1023/A:1015847604654Search in Google Scholar

M. A. Bagger, H. W. Nielsen and E. Bechgaard, Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol, Eur. J. Pharm Sci. 14 (2001) 69-74; DOI: 10.1016/S0928-0987(01)00146-4.10.1016/S0928-0987(01)00146-4Search in Google Scholar